Vor Biopharma (NYSE:VOR – Get Rating) had its price target lowered by Barclays from $15.00 to $10.00 in a research report released on Sunday, The Fly reports. VOR has been the topic of a number of other research reports. Stifel Nicolaus reduced their target price on Vor Biopharma from $17.00 to $16.00 and set a […]
Vor Biopharma (NYSE:VOR – Get Rating) had its target price decreased by Robert W. Baird from $38.00 to $22.00 in a report released on Friday morning, The Fly reports. Robert W. Baird currently has an outperform rating on the stock. VOR has been the topic of several other research reports. JMP Securities reaffirmed a market […]
Vor Biopharma (NYSE:VOR – Get Rating) had its price target decreased by investment analysts at Barclays from $15.00 to $10.00 in a research note issued to investors on Sunday, The Fly reports. Barclays‘s target price would suggest a potential upside of 77.94% from the company’s previous close. Several other equities research analysts have also commented […]
Oppenheimer reaffirmed their outperform rating on shares of Vor Biopharma (NYSE:VOR – Get Rating) in a research report sent to investors on Friday morning, Benzinga reports. They currently have a $18.00 target price on the stock. Oppenheimer also issued estimates for Vor Biopharma’s Q1 2023 earnings at ($0.39) EPS, Q2 2023 earnings at ($0.41) EPS […]
Vor Biopharma (NYSE:VOR – Get Rating) had its target price decreased by HC Wainwright from $20.00 to $17.50 in a report released on Friday morning, The Fly reports. HC Wainwright currently has a buy rating on the stock. Separately, JMP Securities restated a market outperform rating and set a $12.00 target price on shares of […]